

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



Coleman, MP; Rachet, B; Woods, L; Berrino, F; Butler, J; Capocaccia, R; Dickman, P; Gavin, A; Giorgi, R; Hamilton, W; Lambert, P; Peake, MD; Perme, MP; Stare, J; Vedstedt, P (2011) Rebuttal to editorial saying cancer survival statistics are misleading. *BMJ (Clinical research ed)*, 343. d4214. ISSN 0959-8138 DOI: 10.1136/bmj.d4214

Downloaded from: <http://researchonline.lshtm.ac.uk/520/>

DOI: [10.1136/bmj.d4214](https://doi.org/10.1136/bmj.d4214)

Usage Guidelines

Please refer to usage guidelines at <http://researchonline.lshtm.ac.uk/policies.html> or alternatively contact researchonline@lshtm.ac.uk.

Available under license: <http://creativecommons.org/licenses/by-nc-nd/2.5/>

Dear Dr Godlee

**“UK cancer survival statistics are misleading and make survival look worse than it is”:
rebuttal**

This editorial is unfounded, untenable and inconsistent. The *BMJ* editor reports the authors were too busy to defend it¹. The editorial is indefensible. It should be withdrawn.

The editorial is unfounded. The provocative title “*UK cancer survival statistics are misleading and make survival look worse than it is*” is pure conjecture. Conjecture becomes assertion, then conclusion, with no intervening evidence:

“*If* the first months or years of the illness are never traced, the earliest event registered *may be* some aspect of cancer recurrence. The date of this recurrence *would* then be taken as the date from which “survival rates” are calculated. This *makes* [sic] short term survival look misleadingly worse in the UK than in countries such as Sweden ...” [*our emphasis*]

The editorial is untenable. It posits two errors that supposedly make UK cancer survival misleading. Full-scale simulation with the national cancer registry² shows that even implausibly extreme levels of the alleged errors could not account for the UK-Sweden survival deficit. Evidence refutes conjecture.

The editorial is inconsistent: one author published survival estimates for England in 1998-99 using the same cancer registry data criticised in the editorial, without mentioning these criticisms. Survival trends were interpreted (quite reasonably) as reflecting improved treatment³. Data quality has improved substantially since the 1990s⁴. If clinical interpretation of survival estimates derived from the National Cancer Registry was acceptable in 1999, why not now?

A misleading *BMJ* editorial by such eminent authors is not trivial. It is inappropriately cited in support of a criticism⁵ that health policy aimed at improving cancer survival “fails to acknowledge *substantial methodological problems* with studies reporting these [survival] rates” [*our emphasis*]. The editorial undermines research to explain the UK cancer survival deficit, as well as policy designed to reduce the deficit. That is a disservice to cancer patients in the UK.

Michel P Coleman, Professor of Epidemiology and Vital Statistics;

Bernard Rachet, Clinical Senior Lecturer;

Laura Woods, Lecturer, Cancer Research UK Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, Keppel Street, London, UK;

Franco Berrino, Director, Department of Preventive and Predictive Medicine, National Cancer Institute, Milan, Italy;

John Butler, Fellow in Gynaecologic Oncology, St Bartholomew's and Royal Marsden Hospitals, London, UK and Clinical Advisor, International Cancer Benchmarking Partnership;

Riccardo Capocaccia, Cancer Epidemiology Unit, National Centre of Epidemiology, Istituto Superiore di Sanità, Rome, Italy;

Paul Dickman, Associate Professor of Biostatistics, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden;

Anna Gavin, Medical Director, Northern Ireland Cancer Registry, Belfast, UK;

Roch Giorgi, Professor of Biostatistics, Faculty of Medicine, Aix-Marseille University, France;

Willie Hamilton, Professor of Primary Care Diagnostics, Peninsula College of Medicine & Dentistry, Exeter, UK;
Paul Lambert, Reader in Medical Statistics, Centre for Biostatistics & Genetic Epidemiology, Department of Health Sciences, University of Leicester, UK;
Michael D Peake, National Clinical Lead, NHS Cancer Improvement, and Clinical Lead, National Cancer Intelligence Network, Leeds, UK;
Maja Pohar Perme, Assistant Professor, Institute of Biomedical Informatics, University of Ljubljana, Ljubljana, Slovenia;
Janez Stare, Professor of Biostatistics, Medical Faculty, Institute for Biomedical Informatics, University of Ljubljana, Slovenia;
Peter Vedstedt, Professor and Director, Danish Research Centre for Cancer Diagnosis in Primary Care, School of Public Health, Aarhus University, Denmark.

1. Godlee F. Spotlights and letters. *Br Med J* 2010; **341**: c5066 <http://www.bmj.com/content/341/bmj.c5226.short>
2. Woods LM, Coleman MP, Lawrence G *et al*. Evidence against the proposition that "UK cancer survival statistics are misleading": simulation study with national cancer registry data. *Br Med J* 2011; **342**: d3399 <http://www.bmj.com/cgi/doi/10.1136/bmj.d3399>
3. Reeves GK, Beral V, Bull D *et al*. Estimating relative survival among people registered with cancer in England and Wales. *Br J Cancer* 1999; **79**: 18-22
4. UK Association of Cancer Registries. UKACR quality and performance indicators 2009: final. *UKACR* 2010, last accessed 3 June 2011. http://www.ukacr.org/sites/default/files/UKACR%20report2010_final.pdf
5. Whitehead M, Hanratty B, Popay J. NHS reform: untried remedies for misdiagnosed problems? *Lancet* 2010; **376**: 1373-5